Get started
Author

Christopher Kelly

ORCID: 0009-0006-6220-4588
Observed ORCID: 0009-0006-6220-4588
OpenAlex ID: A5110082813
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time
2025 · Diego Salas-Benito, Filippo Birocchi, et al. · Journal for ImmunoTherapy of Cancer · 22
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models
2025 · Filippo Birocchi, Antonio J. Almazan, et al. · Nature Communications · 19
PDF
Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2025 · Alexander Armstrong, Graziella van der Plancke, et al. · Clinical Cancer Research · 3
CAR-T cell therapy targeting MUC17 in gastric tumors
2025 · Sangwoo Park, Cassidy E Ho, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
156 Context-dependent genetic determinants of CAR-T cell fitness revealed by in vivo CRISPR screening
2026 · Filippo Birocchi, Nelson H Knudsen, et al. · Journal for ImmunoTherapy of Cancer
176 Bi-paratopic B7-H3-CAR-T cells to treat metastatic triple negative breast cancer
2026 · Ashlyn T Merce, Alexander J Armstrong, et al. · Journal for ImmunoTherapy of Cancer
157 One mechanism, two applications: synthetic T cell fratricide to mitigate cellular therapy toxicity and treat T cell malignancies
2026 · Filippo Birocchi, Jacob Schwartz, et al. · Journal for ImmunoTherapy of Cancer
Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products
2026 · Viktoria Blumenberg, Kristen B June, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Figure S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S6 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Material S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Table S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Supplementary Figure S6 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Data from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026 · Alexander Armstrong, Graziella van der Plancke, et al.
Works count: 33
Citation count: 46
H-index: 3
I10-index: 2
Year
Topic
Type